SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
SCHEDULE 13G/A
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),
(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2
(AMENDMENT NO. 2)*
Manhattan Pharmaceuticals, Inc.
-----------------------------------
(Name of Issuer)
Common Stock, $0.001 par value
----------------------------------
(Title of Class of Securities)
563118207
(CUSIP Number)
January 30, 2007
------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
| | Rule 13d-1(c)
|X| Rule 13d-1(d)
Page 1 of 7 Pages
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 of otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes)
SCHEDULE 13G
CUSIP No. 563118207 Page 2 of 7 Pages
-------------------------------------------------------------------------------
1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Oleoyl-Estrone Developments SL
-------------------------------------------------------------------------------
2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_|
(b) |_|
-------------------------------------------------------------------------------
3) SEC USE ONLY
-------------------------------------------------------------------------------
4) CITIZENSHIP OR PLACE OF ORGANIZATION
Barcelona, Spain
-------------------------------------------------------------------------------
5) SOLE VOTING POWER
3,957,037
NUMBER ------------------------------------------------------
OF 6) SHARED VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY ------------------------------------------------------
EACH 7) SOLE DISPOSITIVE POWER
REPORTING
PERSON 3,957,037
WITH ------------------------------------------------------
8) SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,957,037
-------------------------------------------------------------------------------
10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
| |
------------------------------------------------------------------------------
11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.6%
-------------------------------------------------------------------------------
12) TYPE OF REPORTING PERSON
CO
-------------------------------------------------------------------------------
SCHEDULE 13G
CUSIP No. 563118207 Page 3 of 7 Pages
-------------------------------------------------------------------------------
1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Joan Pons Gimbert
-------------------------------------------------------------------------------
2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) |_|
(b) |_|
-------------------------------------------------------------------------------
3) SEC USE ONLY
-------------------------------------------------------------------------------
4) CITIZENSHIP OR PLACE OF ORGANIZATION
Spain
-------------------------------------------------------------------------------
5) SOLE VOTING POWER
NUMBER 4,075,816(1)
OF ------------------------------------------------------
SHARES 6) SHARED VOTING POWER
BENEFICIALLY
OWNED BY 0
EACH ------------------------------------------------------
REPORTING 7) SOLE DISPOSITIVE POWER
PERSON
WITH 4,075,816 (1)
------------------------------------------------------
8) SHARED DISPOSITIVE POWER
0
-------------------------------------------------------------------------------
9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,075,816 (1)
-------------------------------------------------------------------------------
10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|-|
-------------------------------------------------------------------------------
11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.8%
-------------------------------------------------------------------------------
12) TYPE OF REPORTING PERSON
IN
-------------------------------------------------------------------------------
--------------------------------
(1) Voting and dispositive power is exercised by Mr. Pons in his capacity as
Chief Executive Officer of Oleoyl-Estrone Developments SL ("OED"). Mr. Pons
disclaims beneficial ownership of the shares owned by OED.
Schedule 13G
------------
Item 1(a). Name of Issuer:
Manhattan Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
810 Seventh Avenue, 4th Floor
New York, New York 10019
Item 2(a). Name of Persons Filing:
Oleoyl-Estrone Developments SL
Joan Pons Gimbert
Item 2(b). Address of Principal Business Office or, if None, Residence:
The business address of Oleoyl-Estrone Developments SL is:
Josep Samitier 1-5
Barcelona Science Park
08028 Barcelona, Spain
The business address of Joan Pons Gimbert is:
c/o Oleoyl-Estrone Developments
Josep Samitier 1-5
Barcelona Science Park
08028 Barcelona, Spain
Item 2(c). Citizenship or Place of Organization:
Oleoyl-Estrone Developments SL is a company of unlimited duration registered in
the Registro Mercantil of Barcelona.
Joan Pons Gimbert is a citizen of Spain.
Item 2(d). Title of Class of Securities:
Common Stock, $0.001 par value per share
Item 2(e). CUSIP Number:
563118207
Item 3. If this statement is filed pursuant to ss.ss. 240.13d-1(b), or
240.13d-2(b) or (c), check whether the person filing is a:
(a) |_| Broker or Dealer Registered Under Section 15 of the Act
(15 U.S.C. 78o)
(b) |_| Bank as defined in section 3(a)(6) of the Act (15
U.S.C. 78c)
(c) |_| Insurance Company as defined in section 3(a)(19) of the
Act (15 U.S.C. 78c)
(d) |_| Investment Company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C. 80a-8)
(e) |_| Investment Adviser in accordance with ss.
240.13d-1(b)(1)(ii)(E)
(f) |_| Employee benefit plan or endowment fund in accordance
with ss. 240.13d-1(b)(1)(ii)(F)
(g) |_| Parent Holding Company or control person in accordance
with ss. 240.13d-1(b)(ii)(G)
(h) |_| Savings Association as defined in ss. 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813)
(i) |_| Church plan that is excluded from the definition of an
investment company under ss. 3(c)(15) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3)
(j) |_| Group, in accordance with ss. 240.13d-1(b)(ii)(J)
Item 4. Ownership.
(a) Amount beneficially owned: 4,075,816 (includes 3,957,037
shares held by Oleoyl-Estrone Developments and 116,667 shares
issuable upon exercise of options which are currently
exercisable.)
(b) Percent of class: 6.8% (based upon 60,147,815 shares
outstanding as reported by the Issuer)
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 4,075,816
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition of:
4,075,816
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
Item 10. Certification.
(a) Not applicable
(b) Not applicable
SIGNATURES
----------
After reasonable inquiry and to the best knowledge and belief of the
undersigned, each of the undersigned certifies that the information set forth in
this Statement is true, complete and correct.
Oleoyl-Estrone Developments SL
By: /s/ Joan Pons Gimbert
-------------------------------
Joan Pons Gimbert
Chief Executive Officer
Joan Pons Gimbert
/s/ Joan Pons Gimbert
----------------------------------
Joan Pons Gimbert
Dated as of February 4, 2007
Agreement of Joint Filing
Pursuant to 13d-1(k) promulgated under the Securities Exchange Act of
1934, as amended, the undersigned hereby confirm the agreement by and among them
to join in the filing on behalf of each of them of a Statement on Schedule 13G
and any and all amendments thereto, and that this Agreement be included as an
Exhibit to such filing.
This Agreement may be executed in any number of counterparts each of which
shall be deemed to be an original and all of which together shall be deemed to
constitute one and the same Agreement.
IN WITNESS WHEREOF, each of the undersigned has executed this Agreement.
OLEOYL-ESTRONE DEVELOPMENTS SL
Dated: February 4, 2007 By: /s/ Joan Pons Gimbert
---------------------------------
Joan Pons Gimbert
Chief Executive Officer
JOAN PONS GIMBERT
Dated: February 4, 2007
/s/ Joan Pons Gimbert
------------------------------------
Joan Pons Gimbert
504902